Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as GBX 19.50 and last traded at GBX 18.72, with a volume of 3932149 shares traded. The stock had previously closed at GBX 17.40.
Scancell Trading Up 9.2%
The firm has a market cap of £209.63 million, a P/E ratio of -36.73 and a beta of 0.57. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The firm’s 50-day simple moving average is GBX 13.17 and its 200 day simple moving average is GBX 11.87.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
See Also
- Five stocks we like better than Scancell
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
